PPT-One-month Ticagrelor Monotherapy After PCI in Acute Coronary Syndromes:

Principal Results From the Doubleblind Placebocontrolled ULTIMATEDAPT Trial Gregg W Stone MD Icahn School of Medicine at Mount Sinai on behalf of ShaoLiang Chen and the ULTIMATEDAPT Investigators. Carrie Hurst FY1. What we’ll cover in next 30 . mins. …. Definitions. Clinical features and differentiating ACS. ECGs. Management. Complications. Some tips from a 2013 Warwick grad. Case study. What is Acute Coronary Syndrome?. . Carotid. . Surgery. Trial. ACST-2. Collaborators. Meeting 2014. Pembroke. College,. Oxford. Is. . recent. . coronary. . stenting. a . problem. (or an . opportunity. ) for . enrolling. the . PLAT. elet Inhibition and patient . O. utcomes trial. Outcomes in patients with a Planned Invasive Strategy. The PLATO trial was funded by AstraZeneca. Invasive. PLATO background. In STEMI and UA/NSTEMI, current guidelines recommend 12 months of aspirin and clopidogrel. 1 2 3 4 5 4 4 4 Month 4 Month Month Month 0.00 Month Month 0.00 0.00 0.00 0.00 Month Month Arizona Arizona fourteen (14) Arizona receipt of this Order Arizona Support Payment Clearinghouse fifty perce د. حسين محمد جمعة . اختصاصي الامراض الباطنة . البورد العربي . كلية طب الموصل . 2010. Key points. The term acute coronary syndrome describes the. bypass grafting in treatment of unprotected left . main stenosis. Nordic–Baltic–British . left main . revascularisation study . (NOBLE. ). A . prospective, randomised, open-label. , non-inferiority trial. Michael C Fraizer, MD. Iowa Heart Center. Feb 4, 2017. Disclosures. AstraZeneca. Mount Sinai Heart. St. Jude Medical. Yale University School of Medicine. Employee-Iowa Heart . Center/Mercy-Des Moines. A . semiquantitative. visual score that will help us to be aware of the anatomical complexity and to anticipate procedural difficulties. One drawback in these comparisons is that there is . heterogencity. Giuseppe . Biondi-Zoccai. , MD. Sapienza University . of. . Rome. , Italy. giuseppe.biondizoccai@uniroma1.it. Learning. . goals. Scope . of. the . problem. Prasugrel. Ticagrelor. Reconciling. the . Coronary Artery Disease. . Includes stable angina and acute coronary syndromes. Ischemia. —. insufficient oxygen supply to meet the requirements of the myocardium. Infarction. —. necrosis or cell death that occurs when severe ischemia is prolonged and decreased perfusion causes irreversible damage to tissue. The BRIGHT-4 Trial. Gregg W. Stone MD. On behalf of . Yaling. Han . and the . BRIGHT-4. investigators. Disclosure Statement of Financial Interest. Dr. Gregg W. Stone. Specific . to this topic: None. PROTEA Trial. Darunavir/r . M. onotherapy. versus Triple Therapy . PROTEA. : Study Design. Source: . Antinori. A, et al. . J Int AIDS Soc. 2014;17:19525.. Darunavir 800 mg QD. + Ritonavir 100 mg . QD. CrCl. : creatinine clearance, CTO: chronic total occlusion, DAPT: dual antiplatelet therapy, DOAC: direct oral anticoagulant, . eDAN. : electronic discharge advice notification, GFR: glomerular filtration rate, HF: heart failure, INR: international normalised ratio, LHP: Leeds Health Pathways, LTHT: Leeds Teaching Hospitals NHS Trust, LV: left ventricular, MACE: major adverse cardiovascular event, MI: myocardial infarction, NICE: National Institute for Health and Care Excellence, NSTEMI: non-ST segment elevation myocardial infarction, STEMI: ST segment elevation myocardial infarction, OD: once daily, PAD: peripheral arterial disease, P2Y12: platelet receptor for adenosine diphosphate PCI: percutaneous coronary intervention, PPI: proton pump inhibitor, SPC: summary of product characteristics, TIA: transient ischaemic attack.. Luis Ortega-Paz, MD, PhD. 1. ; Francesco Franchi, MD. 1. ; Fabiana Rollini, MD1, Mattia Galli, MD. 1. ,. 2. Latonya Been, AAS. 1. , Ghussan Ghanem, MD. 1. , . Awss. . Shalhoub. , MD. 1. , Tiffany Ossi, MD.